Condition
Fecal Immunochemical Test
Total Trials
6
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 1 (1)
Trial Status
Enrolling By Invitation2
Terminated1
Recruiting1
Completed1
Not Yet Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07470658Enrolling By Invitation
Optimal Surveillance Strategy After Positive FIT and Negative Colonoscopy
NCT07183046Not ApplicableNot Yet RecruitingPrimary
Implementation Intention Planning Guide for FIT Colon Cancer Screening
NCT06931860Not ApplicableEnrolling By Invitation
Head to Head Trial of Mailed Cologuard to Mailed FIT
NCT06678477Not ApplicableRecruiting
Comparison of the Performance Between Conventional Colonoscopy and 3D Colonoscopy in Positive Fecal Immunochemical Test Group
NCT03209765Not ApplicableCompleted
WhatsApp Reminder on FIT Compliance
NCT03013855Phase 1TerminatedPrimary
Efficacy of Fecal Immunochemical Test Using Digital Rectal Exam
Showing all 6 trials